Aeterna Zentaris Valuation
Is AEZS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AEZS?
Other financial metrics that can be useful for relative valuation.
|What is AEZS's n/a Ratio?|
Price to Sales Ratio vs Peers
How does AEZS's PS Ratio compare to its peers?
|Company||PS||Estimated Growth||Market Cap|
SBM Sirona Biochem
IBT IBEX Technologies
MBX Microbix Biosystems
KNE Kane Biotech
AEZS Aeterna Zentaris
Price-To-Sales vs Peers: AEZS is good value based on its Price-To-Sales Ratio (4.4x) compared to the peer average (12.3x).
Price to Earnings Ratio vs Industry
How does AEZS's PE Ratio compare vs other companies in the CA Biotechs Industry?
Price to Sales Ratio vs Fair Ratio
What is AEZS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||4.4x|
|Fair PS Ratio||1.2x|
Price-To-Sales vs Fair Ratio: AEZS is expensive based on its Price-To-Sales Ratio (4.4x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).
Share Price vs Fair Value
What is the Fair Price of AEZS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AEZS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AEZS's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.